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Abstract
The natural product α-hydroxytropolones manicol and β-thujaplicinol inhibit replication of herpes 
simplex viruses 1 and 2 (HSV-1 and HSV-2, respectively) at nontoxic concentrations. Because 
these were originally developed as divalent metal-sequestering inhibitors of the ribonuclease H 
activity of HIV-1 reverse transcriptase, α-hydroxytropolones likely target related HSV proteins of 
the nucleotidyltransferase (NTase) superfamily, which share an “RNase H-like” fold. One potential 
candidate is pUL15, a component of the viral terminase molecular motor complex, whose C-
terminal nuclease domain, pUL15C, has recently been crystallized. Crystallography also provided 
a working model for DNA occupancy of the nuclease active site, suggesting potential protein–
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nucleic acid contacts over a region of ∼14 bp. In this work, we extend crystallographic analysis by 
examining pUL15C-mediated hydrolysis of short, closely related DNA duplexes. In addition to 
defining a minimal substrate length, this strategy facilitated construction of a dual-probe 
fluorescence assay for rapid kinetic analysis of wild-type and mutant nucleases. On the basis of its 
proposed role in binding the phosphate backbone, studies with pUL15C variant Lys700Ala 
showed that this mutation affected neither binding of duplex DNA nor binding of small molecule 
to the active site but caused a 17-fold reduction in the turnover rate (kcat), possibly by slowing 
conversion of the enzyme–substrate complex to the enzyme–product complex and/or inhibiting 
dissociation from the hydrolysis product. Finally, with a view of pUL15-associated nuclease 
activity as an antiviral target, the dual-probe fluorescence assay, in combination with differential 
scanning fluorimetry, was used to demonstrate inhibition by several classes of small molecules 
that target divalent metal at the active site.
Graphical abstract
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Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2, respectively) are closely related 
enveloped alphaherpes-viruses with large, double-stranded DNA genomes encoding ∼80 
proteins. Etiologically, HSV-1 is associated with gingivostomatitis, herpetic stromal keratitis, 
and anogenital lesions, while HSV-2, the primary agent of ulcerative anogenital lesions, 
infects ∼20% of individuals in the United States and has been documented to increase the 
frequency of human immunodeficiency virus (HIV) acquisition.1 DNA polymerase has been 
the primary HSV antiviral target, exemplified by the deoxyguanosine analogue acyclovir 
(ACV), the drug of choice for almost 40 years.2 However, an increased incidence of ACV-
refractory HSV keratitis, a leading cause of corneal morbidity in industrialized countries, 
has been reported.3 Recent reports from immunocompetent patients with recurrent herpetic 
keratitis receiving ACV treatment indicate that ACV resistance may be more common that 
previously recognized in this particular population.4 The emergence of viral resistance to 
this class of compounds thus suggests a need for alternative therapies with increased efficacy 
and improved pharmacokinetics.5 Current examples include the HIV-1 protease inhibitor 
nelfinavir, which Kalu et al. showed inhibits late-stage virion envelopment and release.6 
Inhibition of the human cytomegalovirus kinase UL97 by maribavir7 suggests that its HSV 
ortholog, UL13, might also be targeted. The helicase-primase inhibitor pritelivir also 
provides a new class of antiviral compounds distinct from those in current use.8 Finally, 
Krawczyk et al. have suggested the use of humanized antibodies to counter drug-resistant 
HSV.9 On the basis of the effectiveness of combination antiretroviral therapy in treating HIV 
infection, a cocktail of agents for HSV showing acceptable pharmacodynamic profiles and 
distinct molecular targets would be expected to significantly reduce viral load and delay 
acquisition of drug resistance.
Tavis et al. recently reported inhibition of wild-type and ACV-resistant HSV-1 and HSV-2 
replication by several natural product troponoids, including manicol and β-thujaplicinol.10 
Although the viral target was not established, α-hydroxytropolones were previously shown 
to potently inhibit ribonuclease H (RNase H) activity of HIV-1 reverse transcriptase (RT) by 
sequestering the catalytically critical divalent metal at the active site.11–13 Thus, a 
structurally related HSV enzyme seems to be a plausible HSV target. As an example, 
infected cell protein 8 (ICP8), a DNA binding protein required for HSV replication, belongs 
to the superfamily of NTases sharing an “RNase H-like” fold,14 and Yan et al. have shown 
that raltegravir, an inhibitor of HIV-1 integrase (IN), another NTase, blocks replication of 
alpha-, beta-, and gammaherpesviruses.15 A second HSV candidate, pUL15, is a component 
of the terminase molecular motor complex that is responsible for mobilizing viral DNA into 
the capsid. The pUL15 C-terminal nuclease domain (pUL15C) uses a two-metal ion-
mediated catalytic mechanism to cleave and package concatemeric DNA into the virus 
capsid,16 and its recently reported crystal structure17 also highlighted the RNase H-like fold 
common to NTases. Modeling studies with pUL15C17 suggested a binding cleft that could 
accommodate ∼14 bp of duplex DNA, within which residues Arg517, Arg695, Lys700, and 
Lys701 were proposed to interact with the phosphate backbone. Verifying features of the 
active site, as well as investigating whether pUL15 nuclease activity is a therapeutically 
accessible target, requires developing substrates that allow kinetic evaluation and at the same 
time can be adapted to a high-throughput screening (HTS) format. Use of the UL15 C-
terminal domain for such studies is supported by data of Nadal et al., who used a similar 
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domain of human cytomegalovirus (HCMV), UL89 (designated UL89-C), to demonstrate its 
sensitivity to raltegravir.18 However, the previous methodology for assaying nuclease 
activity required cleavage of supercoiled DNA and agarose gel electrophoresis, which is 
time-consuming, challenging to quantify, and impractical for HTS.
Here, we have used several short, closely related oligonucleotide duplexes (∼21 bp) to 
interrogate pUL15C nuclease activity, showing that relatively minor changes can affect both 
the kinetics and specificity of cleavage. Features of this assay were then incorporated into a 
simple and rapid dual-probe fluorescence assay that permitted a detailed kinetic evaluation. 
The dual-probe assay also demonstrated that a single Lys700Ala mutation severely reduced 
pUL15C nuclease activity, possibly by slowing its release from the product of duplex 
cleavage. Finally, by combining differential scanning fluorimetry (DSF) with the dual-probe 
fluorescence assay, we propose two facile screening tools for an HSV nuclease that can be 
extended to the orthologs of other herpesviruses.
Experimental Procedures
General Experimental
All reagents were purchased from commercial sources and used without further purification. 
Recombinant pUL15C was prepared as previously reported.17 α-Hydroxytropolones were 
dissolved in dimethyl sulfoxide (DMSO) and diluted in the same solvent. Oligonucleotides 
were purchased from Integrated DNA Technologies (Coralville, IA) with the exception of 
the dual-labeled HTS oligonucleotide, which was purchased from Biosearch Technologies 
(Petaluma, CA).
Assaying pUL15C Nuclease Activity on Defined DNA Duplexes
Cy5-labeled duplex DNAs were prepared by annealing a 5′ Cy5-labeled 21-nucleotide DNA 
oligonucleotide (Cy5-21D; 5′-ATGTATTTAGGATTGGGACTT-3′) to the following 
complementary strands: 33D, 5′-CACTGCTCAAGAAGTTCCAATCCTAAATACATA-3′; 
28D1, 5′-CTCAAGAAGTTCCAATCCTAAATACATA-3′; 28D2, 5′-
AAGTTCCAATCCTAAATACATACACTGG-3′; 22D, 5′-
AAGTTCCAATCCTAAATACATA-3′; 16D1, 5′-CAATCCTAAATACATA-3′; 16D2, 5′-
CCAATCCTAAATACAT-3′; 16D3, 5′-AAGTTCCAATCCTAAA-3′; 15D, 5′-
CAATCCTAAATACAT-3′; and 14D, 5′-AATCCTAAATACAT-3′. This yielded duplexes 
21D/ 33D, 21D/28D1, 21D/28D2, 21D/22D, 21D/16D1, 21D/ 16D2, 21D/16D3, 21D/15D, 
and 21D/14D. Annealing was performed by heating a mixture containing 10 μM Cy5-21D 
and complementary DNA (10 μM each) in 10 mM Tris-HCl (pH 7.6) and 25 mM NaCl to 
80 °C and slowly cooling it to 4 °C. Nuclease digestion was initiated by incubating 0.1 μM 
duplex DNA in a solution of 20 mM Tris-HCl (pH 7.0), 1 mM MnCl2, 10 mM NaCl, and 0.3 
μM pUL15C at 37 °C and terminated after 5 min by adding an equal volume of 8 M urea. 
Hydrolysis products were fractionated by 15% denaturing urea polyacrylamide gel 
electrophoresis [19:1 acrylamide:bis-(acrylamide)] and visualized by fluorescent imaging 
(Typhoon Trio+, GE Healthcare).
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Dual-Probe Fluorescence Assay of pUL15C Nuclease Activity
The substrate for the dual-probe assay was a doubly labeled 42-nucleotide DNA 
oligonucleotide, Q670-42D-BHQ2plus, 5′-Q670-
TATGTATTTAGGATTGGGATTATACCCAATCCTAAATACATA-BHQ2plus-3′, which 
forms a duplex structure with an intervening hairpin. Denaturation and reannealing were 
performed by heating a mixture containing 10 μM Q670-42D-BHQ2plus, 10 mM Tris-HCl 
(pH 7.6), and 25 mM NaCl to 80 °C and slowly cooling it to 4 °C. To a 96-well plate was 
added 1 μL of each inhibitor, followed by 89 μL of reaction buffer containing the substrate. 
Hydrolysis was initiated by adding 10 μL of 3 μM pUL15C. Final assay conditions were 20 
mM Tris-HCl (pH 7.0), 10 mM NaCl, 1 mM MnCl2, 1% DMSO, 0.3 μM pUL15C, 250 nM 
DNA duplex, and increasing inhibitor concentrations. Wells containing only DMSO were 
used as a control. Plates were incubated at 37 °C in an Infinite M1000 PRO plate reader 
(Tecan) for 10 min, and fluorescence (λex = 646 nm; λem = 670 nm) was measured at 1 min 
intervals such that linear initial rates could be measured in the presence (νi) and absence (νo) 
of inhibitor. Percent inhibition was calculated as 100(νo – νi)/νo and plotted against log[I]. 
IC50 values were calculated using Prism6. All assays were performed in triplicate.
Differential Scanning Fluorimetry (DSF, Thermo-Fluor)
Thermal stability assays were performed according to the method of Nettleship et al.19 To 
each well of a LightCycler480 96-well plate (Roche) was added 1 μL of a 1 mM solution of 
each compound in DMSO, followed by 49 μL of DSF buffer containing 1.6 μM pUL15C, 20 
mM HEPES (pH 7.5), 10 mM MgCl2, 100 mM NaCl, and a 1:2000 dilution of SYPRO 
Orange dye (Invitrogen). The mixture was heated from 30 to 80 °C in increments of 0.2 °C. 
The fluorescence intensity was measured using excitation and emission wavelengths of 483 
and 568 nm, respectively. Compound-induced changes in thermal stability (ΔTm) were 
analyzed using LightCycler 480 Software. All assays were performed in duplicate.
Michaelis–Menten Kinetic Analysis
Inhibitory activities of compound 21 and raltegravir were measured with the dual-probe 
fluorescence assay in the presence of varying concentrations of substrate (50–2000 nM). 
Concentrations of compound 21 and raltegravir used were 0, 0.1, 0.2, and 0.4 μM and 0, 0.5, 
1.0, and 2.0 μM, respectively. Wells containing only DMSO were used as a control. Initial 
velocities were obtained at an enzyme concentration (0.3 μM) that ensured a linear 
relationship between relative fluorescence unit (RFU) and incubation time. Kinetic 
parameters were determined using Prism6. Lineweaver–Burk plots were constructed by 
plotting reciprocals of initial velocity against the reciprocal of substrate concentration. All 
assays were performed in triplicate.
α-Hydroxytropolone IC50 Determination by Agarose Gel Electrophoresis
pUL15C nuclease activity was initiated by incubating 400 ng of supercoiled pCMV-Kan 
plasmid (a generous gift of B. Felber, National Cancer Institute, Bethesda, MD) in 10 μL of 
buffer containing 0.12 μM pUL15C, 20 mM Tris-HCl (pH 7.0), 1 mM MnCl2, 10 mM NaCl, 
10% DMSO, and increasing concentrations of inhibitor at 37 °C and terminated after 10 min 
with 5 μL of 100 mM EDTA. Hydrolysis products were separated by 0.8% agarose gel 
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electrophoresis and visualized by ethidium bromide staining. The proportion of supercoiled 
DNA breakage was quantified using ImageQuant (GE Healthcare), and IC50 values were 
calculated using Prism6 (GraphPad Software).
Yonetani–Theorell Analysis.20
To determine whether the binding sites for compound 21 and raltegravir overlap, nuclease 
activity was measured in the presence of varying concentrations of compound 21 (0–0.4 μM) 
and raltegravir (0–2.0 μM). Data analysis was performed using Prism6, and the following 
equation was used:
where νij is the enzyme velocity in the presence of both compounds at concentrations [I] and 
[J] and γ is the interaction term that defines the degree to which binding of one compound 
perturbs binding of the other. All assays were performed in triplicate.
Order-of-Addition Analysis
The inhibitory activity of compound 21 was evaluated under conditions where the overall 
composition of the reaction mixture was unchanged, but the order in which individual 
components (enzyme, divalent metal, nucleic acid, and inhibitor) were mixed was varied. 
Preincubation was conducted at room temperature for 10 min. Reaction mixtures were 
incubated at 37 °C in an Infinite M1000 PRO plate reader for 20 min, and fluorescence was 
measured at 1 min intervals.
α-Hydroxytropolone Synthesis
α-Hydroxytropolones 1–10 and 12–20 in Figure 2b were synthesized and characterized as 
previously described.21–23 Synthesis of compounds 11 and 21 is provided in the Supporting 
Information.
Results
Defining a Minimal Substrate Length for pUL15C
Nonspecific cleavage of supercoiled DNA and fractionation of the hydrolysis products by 
agarose gel electrophoresis has been the standard method for studying the nuclease domains 
of herpesvirus terminases.17,18 However, because our goal was biochemical characterization 
of HSV pUL15C as a prerequisite to developing an HTS platform, defining a simple 
minimal-length substrate was important. In this respect, modeling studies with pUL15C17 
propose the substrate binding cleft accommodates ∼14 bp of duplex DNA. With respect to 
cleavage specificity, pac motifs, which contribute to the genome cleavage/packaging 
process, have been characterized as containing adjacent G:C and A:T blocks.24 We therefore 
used this information to design the 21-nucleotide/33-nucleotide DNA duplex of Figure 1 
whose lower, 33-nucleotide strand either varied in length or relocated the position of the 
single-stranded overhang.
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pUL15C-mediated digestion of the test Cy5-21D/33D duplex yielded major products of 10 
and 12 nucleotides and smaller amounts of 11-, 13-, and 14-nucleotide products, indicative 
of cleavage within the 5′-G-G-A-T-T-G-G-3′ sequence (Figure 1). Altering the length of the 
single-stranded overhang at the 5′ terminus (duplex 21D/28D1) or repositioning the 
overhang to the 3′ terminus (duplex 21D/ 28D2), while retaining a 21 bp duplex, did not 
affect the specificity of cleavage, although a slight decrease in cleavage kinetics was 
observed with 21D/28D1. A similar observation was made with duplex 21D/22D, suggesting 
terminal overhangs do not significantly contribute to substrate binding. In contrast, we 
observed significant alterations in cleavage kinetics as the length of the duplex region was 
progressively reduced. The lower strands of duplexes 21D/16D2, 21D/15D, and 21D/14D 
share the same 3′ termini, but their 5′ termini were deleted such that duplex length was 
reduced to 16, 15, and 14 bp, respectively. Consequently, the upper strand 5′-G-G-A-T-T-G-
G-3′ motif of 21D/16D2 is fully base-paired but reduced to 5′-G-G-A-T-T-G-3′ and 5′-G-G-
A-T-T-3′ on 21D/15D and 21D/14D, respectively. With duplexes 21D/15D and 21D/ 14D, 
we observed a gradual increase of the amount of uncleaved duplex, which was most 
pronounced with 21D/14D. These results indirectly suggest that a minimal duplex length of 
14–15 bp is required for optimal positioning within the pUL15C active site. This notion of a 
minimal substrate size was strengthened by observations with duplex 21D/16D1. Although 
the lower-strand oligonucleotide is 16 nucleotides in length, it provided a 15 bp duplex 
together with a single-nucleotide 3′ overhang. As a result, hydrolysis kinetics of 21D/ 16D1 
were also slightly reduced. In the model of pUL15C complexed with duplex DNA,17 two 
hairpins, comprising residues 620–633 and 684–704, are separated by ∼13 bp, which lends 
support to the data depicted in Figure 1. Finally, substrate 21D/16D3 maintains a duplex 
length of 16 bp but relocates this such that its 5′ terminus is blunt-ended. In this case, 
cleavage kinetics were reduced and accompanied by a relaxed hydrolysis profile, yielding 
products ranging from 10 to 18 nucleotides in length. Despite prolonged cleavage, levels of 
the 10- and 11-nucleotide product were significantly reduced on this substrate. 
Supplementary Figure 1 provides a similar analysis, but one performed on duplexes whose 
lower strand was 5′ 32P end-labeled. For duplex 21/33D*, cleavage was restricted primarily 
to the complementary 3′-C-C-T-A-A-C-C-5′ motif. Although cleavage kinetics of duplex 
21/22D* were slightly reduced, a similar observation was made for duplexes 21/28D1*, 
21/28D2*, and 21/22D*, suggestive of double-stranded scission throughout this 7 bp motif. 
Cleavage kinetics of duplexes 21/16D*, 21/15D*, and 21/14D* were again reduced, with 
specificity centering around the 3′-T-C-C-5′ sequence, supporting our contention that 
efficient pUL15C recognition requires duplex DNA longer than this minimal length. The 
rationale for enzyme “slippage” and broadened cleavage specificity is not immediately clear.
A Dual-Probe Fluorescence Assay of pUL15C Nuclease Activity
As discussed earlier, cleavage of supercoiled DNA followed by agarose gel electrophoresis 
has been used to evaluate nuclease activity of pUL15C and related terminases.17,18 As the 
significance of herpesvirus capsid assembly proteins as therapeutic targets grows,25 a gel-
based approach to identifying small molecule antagonists would clearly be impractical. We 
therefore elected to take advantage of the duplex cleavage data depicted in Figure 1 to 
design a “minimal” substrate for pUL15C that would allow detailed kinetic evaluation and 
provide a simple HTS substrate.
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Attempts to locate a fluorescence donor/quencher pair at either end of an 18 bp duplex were 
unsuccessful, possibly reflecting their separation distance or interaction with the viral 
nuclease (data not shown). Consequently, we designed the 42-nucleotide single-stranded 
DNA of Figure 2a containing adjacent G:C- and A:T-rich blocks. We elected to retain the 
neighboring A:T-rich portion of the duplex, reasoning that it separated the pUL15C 
recognition site from bulky modifications introduced at the DNA termini. These 
modifications included the indocarbocyanine Quasar 670 (Q670), which fluoresces in the 
red region of the visible spectrum, at the 5′ terminus and Black Hole Quencher 2 Plus 
(BHQ2plus) at the 3′ terminus. Following hydrolysis, we reasoned that residual duplex DNA 
containing the Q670/BHQ2plus pair would spontaneously dissociate at room temperature, 
allowing us to monitor hydrolysis via relief from quenching and increased fluorescence 
intensity. Our hypothesis was borne out by data depicted in Figure 2b, performed at different 
pUL15C concentrations. As a control, the signal from a complete DNase I digestion of the 
substrate was compatible with that achieved with pUL15C at 40 ng/μL (1.2 μM), showing 
that the reaction proceeded to completion (data not shown). To eliminate the possibility of 
low-level DNase I contamination, we exploited our observation that pUL15C was 
considerably more active in the presence of Mn2+ than in the presence of Mg2+. In 
Supplementary Figure 2, we compared a Mg2+-dependent pUL15C digest of substrate 
21D/33D (lanes a–c) with that catalyzed by DNase I under the same condition (lanes d and 
e). The absence of hydrolysis products with the former despite prolonged incubation 
supports the notion that activity observed with the 21D/33D duplex indeed derived from 
pUL15C. In support of this, and in contrast to pUL15C, cleavage of substrate 21D/33D by 
DNase I in the presence of 1 mM Mn2+ was insensitive to inhibition by β-thujaplicinol at a 
concentration of 20 μM (Supplementary Figure 2b,c).
Characterization of Wild-Type and Mutant pUL15C
Modeling of duplex DNA into the active site of pUL15C suggests “loop 4” residues Arg695, 
Lys700, and Arg701 are sufficiently close to the phosphate backbone to engage in direct 
contact.17 To investigate this role for Lys700, the pUL15C variant containing a Lys700Ala 
mutation was purified and analyzed. We first assessed the integrity of wild-type and mutant 
protein by DSF (ThermoFluor), which monitors binding of the environmentally sensitive dye 
SYPRO orange as a function of temperature, providing a melting temperature (Tm).19 As 
HSV pUL15C belongs to the superfamily of NTases, which includes HIV RNase H, 
alterations to the thermal stability of both proteins were also determined in the presence of 
the RNase H active site inhibitor β-thujaplicinol.11 Because Lys700 does not constitute an 
active site residue, we expected both proteins to behave similarly in the absence and 
presence of the active site ligand, a notion that was confirmed by data depicted in panels a 
and b of Figure 3. In the absence of β-thujaplicinol, DSF yielded Tm values of 55.72 and 
56.11 °C for wt and mutant protein, respectively, while incubation in the presence 20 μM β-
thujaplicinol stabilized both proteins, increasing the Tm of the wt enzyme by 4.69 °C and 
that of the Lys700Ala mutant by 4.30 °C. Thus, to a first approximation, DSF confirmed that 
the active site architecture of Lys700Ala pUL15C was not compromised.
We next used the dual-probe fluorescence assay to kinetically characterize the wild-type and 
mutant nucleases. As shown in Figure 3c, the activity of Lys700Ala pUL15C was reduced to 
Masaoka et al. Page 8













∼8% of that of the wild-type enzyme. Interestingly, Km values for both proteins were not 
significantly different (0.71 ± 0.03 μM for wt and 0.54 ± 0.02 μM for the Lys700Ala 
mutant), suggesting that loss of activity was not a result of a reduced affinity for substrate. In 
contrast, ∼17- and ∼13-fold differences were observed in the turnover number (kcat values 
of 2.6 ± 0.1 min−1 for wt and 0.16 ± 0.01 min−1 for Lys700Ala) and the catalytic efficiency 
[kcat/Km values of (6.2 ± 0.3) × 104 M−1 s−1 for wt and (0.48 ± 0.04) × 104 M−1 s−1 for 
Lys700Ala], respectively. Possible explanations for these differences are that altering Lys700 
decreases the rate of conversion of the enzyme–substrate complex to the enzyme–product 
complex and/or affects the off rate of the mutant enzyme from the cleaved duplex.
α-Hydroxytropolone Inhibition of pUL15C
Tavis et al. have demonstrated that the natural product α-hydroxytropolones manicol and β-
thujaplicinol suppress replication of wild-type and ACV-resistant HSV-1 and HSV-2 at 
noncytotoxic concentrations, illustrating their antiviral potential.10 On the basis of our 
interest in developing inhibitors directed toward a broader class of viral 
nucleotidyltransferases,26 the 21 novel β-thujaplicinol derivatives of Figure 4, substituted on 
their heptatriene ring while the metal binding pharmacophore is preserved, were 
synthesized. For comparative purposes, we initially monitored pUL15C inhibition by a 
subset of these compounds via agarose gel electrophoresis, the standard method of choice. 
This approach (Figure 5) yielded IC50 values ranging from 0.61 μM (compound 6) to 7.3 μM 
(compound 10), compared to 2.0 μM for the parent β-thujaplicinol. While agarose gel 
electrophoresis suggests that the bulkier substitution of compound 10 may sterically impede 
binding, quantification of such data is challenging, and its applicability to HTS is 
impractical. In contrast, the dual-probe fluorescence assay of Figure 6 circumvents these 
limitations. In this case, IC50 values ranged from 0.14 ± 0.01 μM (compound 5) to 49.1 
± 17.0 μM (compound 10). Although the submicromolar values obtained for compounds 1, 
6, 14, and 21 were in keeping with data from agarose gel electrophoresis, there was 
significant variance in the absolute IC50 values, which we attributed to the difficulty in 
quantifying data from agarose gel electrophoresis. Likewise, the poor activity of compound 
10 when analyzed by gel electrophoresis (IC50 = 7.3 μM) was confirmed by the dual-probe 
assay (IC50 = 49.1 ± 17.0 μM), although the absolute values differed almost 7-fold. Other 
possible reasons for these discrepancies might be the difference between using a large 
supercoiled DNA as opposed to a short duplex as a substrate, or the fact that supercoiled 
DNA provides significantly more pUL15C binding sites compared to the 15–20 bp 
substrates we have used.
Although the number of α-hydroxytropolones evaluated as pUL15C inhibitors may be too 
small to derive structure–activity relationships, a pattern emerges in which smaller ester or 
ketone substitutions at position 3 and/or 4 of the heptatriene ring (compounds 1–6, 13, 15, 
and 21) are significantly more potent than larger analogues (11 and 16) or those with direct 
aromatic substitutions (compounds 7–10 and 17–20). This trend suggests that steric 
problems associated with the latter impede the correct positioning of the metal binding 
pharmacophore at the nuclease active site. For those compounds with submicromolar 
activity, substituting position 5 of the heptatriene ring with -CH3 (1), -CH2Cl (2), and -
CH2OCH3 (3) minimally affected the IC50, suggesting this position may be amenable to 
Masaoka et al. Page 9













further modification to improve potency. Furthermore, the general trend of lower activity 
among those with direct aromatic substitution (7–10, 12, and 17–20) compared to the 
activity of those with ketones (5, 6, 11, and 14–16) or esters (1–4, 13, and 21) suggests that 
electronic effects of the substituents directly on the troponoid ring may be an important 
factor in determining potency. Indeed, comparing 4 with closely related compounds 1, 13, 
and 21 suggests that adding an electron-withdrawing group such as an ester (1) or bromide 
(21) directly to the tropolone enhances activity, whereas adding an electron-donating methyl 
group (13) decreases activity. Among analogues that have direct aromatic substitution (7–10, 
12, and 17–20), compound 7, with a highly electron-withdrawing nitro group, is the most 
potent. Understanding the nuances of α-hydroxytropolone inhibition of pUL15C will require 
analysis of additional analogues, but the initial trends provide directions for further studies.
The ThermoFluor strategy that monitors protein stability in the presence of small molecule 
ligands is finding increased utility in drug discovery.27 As a complement to the IC50 values 
provided by the dual-probe fluorescence assay, we investigated how this correlated with 
ligand-induced alterations in pUL15C stability. As shown in Figure 6b, and consistent with 
reports on their interaction with retroviral RNase H,28 α-hydroxytropolones stabilized 
pUL15C against thermal denaturation. ΔTm values ranged from 2.35 °C (compound 10) to 
8.70 °C (compound 21), which were among the least and most potent chemotypes, 
respectively. In general, we observed a good correlation between ΔTm and IC50 values, 
underscoring the value of differential scanning fluorimetry as a facile tool for ranking the 
efficacy of inhibitor binding. Mechanistically, an enhanced Tm may reflect decreased 
accessibility of the nucleic acid to the active site of the enzyme–inhibitor complex or 
stabilization of the enzyme–inhibitor–substrate complex in a configuration incompatible 
with hydrolysis.
Kinetic Analysis of pUL15C Inhibition
The robustness and reproducibility of our dual-probe fluorescence assay also allowed a 
kinetic evaluation of α-hydroxytropolone-mediated HSV pUL15C inhibition. The 
Lineweaver–Burke plot of Figure 7a suggests compound 21 is a noncompetitive inhibitor (Ki 
= 0.14 ± 0.01 μM), binding to the enzyme and the enzyme-substrate complex. This 
observation is significant because studies investigating α-hydroxytropolone-mediated 
inhibition of HIV-1 RNase H have indicated that binding to a preorganized enzyme-substrate 
complex is compromised, potentially limiting their therapeutic usefulness.29,30 Figure 7b 
presents a Yonetani–Theorell plot determined with compound 21 and the HIV-1 IN inhibitor 
raltegravir, a diketo acid that also sequesters divalent metal at the active site.31 The parallel 
nature of the plots indicates that the two molecules are mutually exclusive; i.e., they share a 
common binding site. Finally, Figure 8c examined whether the order in which enzyme (E), 
inhibitor (I), substrate (S), and divalent metal (M) were added affected pUL15C inhibition 
by compound 21. In the presence of an inhibitor, the rate of substrate degradation was 
unaffected regardless of the order of addition, confirming that the preformed enzyme–
substrate complex could be accessed by the small molecule, in contrast to results with HIV-1 
RNase H.
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Diketo Acid and Naphthyridinone Inhibition of pUL15C
In view of the common RNase H-like fold of herpesvirus NTases and HIV-1 IN, Nadal et 
al.18 and Yan et al.15 demonstrated inhibition of herpesvirus replication by different classes 
of diketo acid-based IN inhibitors. The dual-probe fluorescence assay therefore allowed us 
to make a direct comparison between these two inhibitor classes. For comparative analysis, 
we chose compound 21, which was one of the most potent α-hydroxytropolones. In the 
assay depicted in Figure 8a, its IC50 value of 0.13 ± 0.01 μM was slightly improved over that 
reported in Figure 6b. For diketo acids raltegravir (RAL) and dolutegravir (DTG), we 
calculated IC50 values of 0.39 ± 0.05 and 1.10 ± 0.09 μM, respectively. Figure 8b shows a 
Lineweaver–Burke plot determined in the presence of raltegravir, indicating that, similar to 
compound 21, it noncompetitively inhibits pUL15C (Ki = 1.0 ± 0.1 μM). Interestingly, data 
depicted in Figure 8b indicate that while these diketo acids also stabilized pUL15C against 
thermal denaturation, the magnitude of stabilization was significantly lower compared to 
that of compound 21. In contrast, elvitegravir (EVG) and MK2048, the latter of which is a 
second-generation diketo acid that is reportedly superior to raltegravir,32 were significantly 
less potent, having IC50 values in excess of 10 μM. Of note, these poorly active diketo acids 
had a destabilizing effect on pUL15C, in both instances decreasing the Tm by ∼0.5 °C.
Finally, the metal sequestering properties of naphthyridinone-based compounds have led to 
their investigation as inhibitors of HIV-1 RNase H and IN,22,33 as well as their potential 
repurposing as anticancer agents.34 We therefore tested this inhibitor class against pUL15C, 
the results of which are shown in Figure 9. IC50 values varied more that 40-fold, ranging 
from 0.12 ± 0.002 μM (compound 23) to 5.2 ± 0.4 μM (compound 25). While the 
requirement for the C4 OH remains to be validated, a clear pattern that emerges is reduced 
potency when it is replaced by bulkier substituents. Interestingly, and consistent with the 
data depicted in Figures 4 and 6, introducing an ester at position C3 is well tolerated, 
suggesting this position of the naphthyridine ring could be further derivatized without 
compromising its metal sequestering properties. In summary, data depicted in Figures 6–9 
provide a strong case for targeting the catalytically critical divalent metal cofactor of 
pUL15C, for which the dual-probe fluorescence and ThermoFluor assays described here will 
find utility.
Discussion
In addition to the need for second-generation therapies with increased efficacy and improved 
pharmacokinetics for the treatment of drug resistance issues associated with HSV-1 and 
HSV-2 infections, a growing body of evidence suggests that HSV-2 infection can stimulate 
macrophages in vitro and induce HIV-1 replication in these cells. Developing a microbicide 
with efficient suppressive activity against HSV-2 for use in combination with an HIV-1 
microbicide would therefore seem highly desirable. Progress in both areas would benefit 
from an improved understanding of herpesvirus proteins that mediate entry, genome 
replication, and capsid assembly. In this work, we have characterized pUL15C, the C-
terminal nuclease domain of the viral terminase, with a view of targeting herpesvirus 
genome processing and packaging as an antiviral strategy. Because the parent protein, 
pUL15, and its homologues are highly conserved among all family members, small 
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molecule antagonists evaluated here may have broader utility as antiviral agents for 
herpesvirus-associated disease.25
Central to our studies has been investigating substrate requirements for pUL15C; data 
depicted in Figure 1 illustrate the efficient cleavage of a “minimal” 14 bp duplex containing 
an A:T-rich segment flanked by G:C-rich segments. Although we must recognize that 
substrate length and/or sequence specificity may vary in the context of full-length pUL15, 
use of short duplexes such as those shown in Figure 1 allows alterations to sequence and/or 
structure to be analyzed by introducing targeted nucleoside analogue substitutions. 
Examples include (a) imposing increased rigidity or flexibility on the duplex (locked nucleic 
acids or pyrimidine isosteres, respectively), (b) charge neutralization via methylphosphonate 
linkages, or (c) removing nucleobases, leaving the sugar–phosphate backbone (abasic 
deoxyribosides). This approach has been successfully applied in analyzing substrate 
requirements of the reverse transcriptases of HIV-135,36 and the Saccharomyces cerevisiae 
LTR retrotransposon Ty3,37 as well as the cellular deaminase APOBEC3G.38 In the absence 
of a DNA-containing cocrystal, a nucleoside analogue strategy can provide important 
mechanistic details about the interaction of pUL15C with duplex DNA.
This possibility aside, an important outgrowth of our investigation has been development of 
a simple, inexpensive dual-probe fluorescence assay (Figure 2) for biochemical 
characterization of pUL15C as well as a robust HTS platform. Examples of the former are 
provided by kinetic analysis of the wild-type nuclease and a Lys700Ala mutant substituted at 
a residue implicated in contacting the DNA phosphate backbone, while use of the assay as 
an HTS tool is demonstrated by our investigation of α-hydroxytropolone, diketo acid, and 
naphthyridinone inhibition of pUL15C nuclease activity. The latter application of the dual-
probe assay is particularly important, because cleavage of supercoiled DNA and 
fractionation of the products by agarose gel electrophoresis has been the general method of 
choice for studying the activity of herpesvirus nucleases. Adapting this or any related gel-
based assay to an HTS format would present a significant practical obstacle, and comparison 
of the data depicted in Figures 5 and 6 shows that, for α-hydroxytropolones, the inhibitory 
trend observed by agarose gel electrophoresis is reproduced in the dual-probe fluorescence 
assay. Our fluorescence assay has been complemented by DSF, analyzing the effect of small 
molecule binding on pUL15C thermal stability. Data depicted in Figure 6 show that α-
hydroxytropolone binding results in stabilization against thermal denaturation, with ΔTm 
values varying from 2.35 °C (compound 10) to 8.70 °C (compound 21). Equally important 
was the observation that ΔTm values correlate well with the inhibitory potency of these 
compounds (49.1 ± 17.0 μM for compound 10 vs 0.17 ± 0.002 μM for compound 21). 
Because DSF requires modest amounts of protein and utilizes common laboratory 
instrumentation, this provides a complementary, cost-effective alternative HTS strategy that 
should find use in evaluating related nucleases. Understanding the structural basis for ligand-
induced stabilization, and its link to inhibitory potency, will require obtaining a cocrystal of 
pUL15C containing selected α-hydroxytropolones. Conceivably, this could occur through an 
increased number of contacts with divalent metal at the active site, providing a stabilizing 
effect on the protein while “freezing” its mobility, thereby interrupting catalysis.
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Although we have evaluated a relatively small number of compounds, examining three 
structural classes of small molecules provides important insights into inhibition of pUL15 
nuclease activity. For α-hydroxytropolones, relatively small substituents on the heptatriene 
ring appear to be most favorable, suggesting steric interference is caused by the bulkier 
substitutions. This notion can be extended to naphthyridinones, where bulkier aromatic 
substitutions again resulted in reduced potency. Although speculative, comparing IC50 
values for compounds 23, 26, and 27 suggests that combining small substituents at positions 
C1 and C2 could provide increased potency. Finally, although our biochemical analysis 
suggests that a component of the viral terminase molecular motor is a target of α-
hydroxytropolone inhibition in vitro, confirmation of this will require selection of a drug-
resistant variant and mapping of the inactivating lesion. In this respect, Zhou et al. have 
documented mutations in 16 HSV-1 open reading frames following prolonged exposure to 
the HIV-1 IN inhibitor raltegravir.39 Of these, a Val296Ile mutation in UL42, encoding the 
DNA polymerase accessory factor, was sufficient to confer raltegravir resistance. Because 
crystallographic studies have not revealed the common RNase H-like fold of NTases for 
UL42, this could suggest an alternative mode for raltegravir-mediated HSV inhibition. At 
the same time, this suggests a cocktail of small molecule antagonists with divalent metal 
sequestering properties might provide an effective combination antiviral strategy.
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Refer to Web version on PubMed Central for supplementary material.
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pUL15C cleavage of a 21-nucleotide/33-nucleotide DNA duplex and variants thereof. 
Sequence of duplex DNA substrates (left). Asterisks denote the positions of the Cy5 label. 
Cleavage patterns of specificity (right), following incubation with pUL15C for 5 and 30 min 
(lanes a and b, respectively). A summary of the primary cleavage sites (trianges) is 
illustrated above each duplex sequence.
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(a) Design of a dual-probe fluorescence substrate to evaluate pUL15C nuclease activity. The 
shaded region of the duplex represents cleavage sites defined by the substrate analysis of 
Figure 1. Abbreviations: Q670, Quasar 670 fluorescence donor; BHQ, Black Hole Quencher 
2 Plus. (b) pUL15C-mediated cleavage of the dual-probe substrate as a function of 
increasing enzyme concentration.
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Charactarization of wild-type and Lys700Ala pUL15C. Differential scanning fluorimetry 
analysis of (a) wild-type and (b) mutant enzymes in the absence (gray trace) and presence of 
20 μM β-thujaplicinol (black trace). (c) Duplex DNA cleavage activity and kinetic analysis 
of pUL15C using the dual-probe fluorescence assay. Enzyme activity was determined at 
protein concentrations of 0.6 μM (columns 1 and 3) and 0.3 μM (columns 2 and 4). Km, kcat, 
and kcat/Km values for both are provided in the inset.
Masaoka et al. Page 19














Structures of synthetic β-thujaplicinol derivatives. β-TP, β-thujaplicinol.
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Inhibition of pUL15C nuclease activity by selected α-hydroxytropolones, analyzed by 1% 
agarose gel electrophoresis and ethidium bromide staining. Each compound was tested at a 
final concentration of 0.006, 0.032, 0.16, 0.80, 4.0, and 20.0 μM. The migration positions of 
supercoiled, open circular, and linear plasmid DNA are designated S, O, and L, respectively. 
Lane C1, no pUL15C; lane C2, pUL15C without inhibitor. IC50 values for all compounds 
are presented under their respective panel. β-TP, β-thujaplicinol.
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Analysis of α-hydroxytropolone inhibition of pUL15C nuclease activity using the dual-
probe fluorescence assay. (a) Representative dose–response curves for β-thujaplicinol (Δ) 
and compound 21 (□). (b) Comparison of IC50 and ΔTm values of compounds 1–21 and β-
thujaplicinol (β-TP).
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Kinetic analysis of pUL15C inhibition. (a) Michaelis–Menten kinetic plot of pUL15C 
nuclease activity in the presence of various compound 21 concentrations: 0.1 (△), 0.2 (□), 
and 0.4 μM (◇). Empty circles represent the no inhibitor control. The graph is representative 
of three independent experiments. A Lineweaver–Burke plot is presented in the inset, 
indicating compound 21 is a noncompetitive inhibitor. (b) Yonetani–Theorell plot for 
compound 21 and RAL. The inhibitory activity (defined as νo/νi) for each concentration of 
compound 21 (0, 0.1, 0.2, 0.4, and 0.8 μM) is plotted as a function of the concentration of 
RAL (0, 0.25, 0.5, 1, and 2 μM). The assay was performed at fixed concentrations of 
substrate (250 nM). Parallel lines for the two inhibitors indicate they are mutually exclusive. 
(c) Effect of the order of addition on the pUL15C activity of compound 21. The inhibitory 
activity of compound 21 was evaluated under seven different conditions, having the same 
composition but different order of addition of enzyme (E), substrate (S), Mn2+ (M), and 
inhibitor (I): preincubation of E and M, hydrolysis initiated with S (○); E alone, hydrolysis 
initiated with S and M (△); preincubation of E and S, hydrolysis initiated with M (□); 
preincubation of E, M, and I, hydrolysis initiated with S (●); preincubation of E and I, 
hydrolysis initiated with S and M (■); preincubation of E and S, hydrolysis initiated with M 
and I (▲); and preincubation of E, S, and I, hydrolysis initiated with M (◆). Preincubation 
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was conducted at room temperature for 10 min. Reaction mixtures were incubated at 37 °C 
in an Infinite M1000 PRO plate reader for 20 min, and fluorescence was measured at 1 min 
intervals.
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α-Hydroxytropolone vs diketo acid inhibition of pUL15C nuclease activity. (a) Chemical 
structures of HIV-1 IN inhibitors, raltegravir (RAL), dolutegravir (DTG), elvitegravir 
(EVG), and MK2048. (b) IC50 and ΔTm values of α-hydroxytropolone 21 and diketo acids. 
IC50 and ΔTm values are the average of triplicate and duplicate experiments, respectively. (c) 
Lineweaver–Burke plot of pUL15C nuclease activity in the presence of various RAL 
concentrations: 0.25 △, 0.5 (□), and 1.0 μM (◇). Empty circles represent the no inhibitor 
control. Nuclease activity of pUL15C was measured using the dual-probe fluorescence assay 
at varying substrate concentrations (100, 150, 250, 500, 1000, and 2000 nM). Similar 
intersection points on the x-axis in the absence and presence of RAL indicate 
noncompetitive inhibition. The graph is representative of three independent experiments.
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Napththyridinone inhibition of pUL15C nuclease activity. IC50 values are the average of 
triplicate experiments.
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